4-[(benzyloxycarbonylamino)methyl]-1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid | 1192189-66-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[(benzyloxycarbonylamino)methyl]-1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid
• 英文别名: 4-((benzyloxycarbonylamino)methyl)-1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid；4-({[(Benzyloxy)carbonyl]amino}methyl)-1-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid；1-[(2-methylpropan-2-yl)oxycarbonyl]-4-(phenylmethoxycarbonylaminomethyl)piperidine-4-carboxylic acid
• CAS: 1192189-66-4
• 化学式: C₂₀H₂₈N₂O₆
• 分子量: 392.452
• InChiKey: JGYXGJTYLWHYOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  105
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-[(benzyloxycarbonylamino)methyl]-1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid 在 N,N-二甲基甲酰胺 吡啶 、 草酰氯 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE

  摘要：

  LIM激酶2的抑制剂已被披露，以及包含它们的药物组合物和它们的使用方法。特定化合物的化学式如下：

  公开号：

  US20090264450A1
• 作为产物：
  描述：

  1-叔丁基4-乙基4-氰基哌啶-1,4-二羧酸 在 platinum(IV) oxide 、 水 、 氢气 、 碳酸氢钠 、 sodium hydroxide 作用下， 以 乙醇 、 二氯甲烷 、 溶剂黄146 为溶剂， 生成 4-[(benzyloxycarbonylamino)methyl]-1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid
  参考文献：
  名称：

  Synthesis and biological evaluation of 4-piperidinecarboxylate and 4-piperidinecyanide derivatives for T-type calcium channel blockers

  摘要：

  To obtain selective and potent inhibitor for T-type calcium channel by ligand based drug design, 4-piperidinecarboxylate and 4-piperidinecyanide derivatives were prepared and evaluated for in vitro and in vivo activity against alpha(1G) calcium channel. Among them, several compounds showed good T-type calcium channel inhibitory activity and minimal off-target activity over hERG channel (% inhibition at 10 mu M = 61.85-71.99, hERG channel IC50 = 1.57 +/- 0.14-4.98 +/- 0.36 mu M). Selected compound 31a was evaluated on SNL model of neuropathic pain and showed inhibitory effect on mechanical allodynia. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.07.087

文献信息

• LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE
  申请人：Burgoon Hugh Alfred

  公开号：US20090264450A1

  公开（公告）日：2009-10-22

  Inhibitors of LIM kinase 2 are disclosed, along with pharmaceutical compositions comprising them and methods of their use. Particular compounds are of the formula:

  LIM激酶2的抑制剂已被披露，以及包含它们的药物组合物和它们的使用方法。特定化合物的化学式如下：
• LIMK2 inhibitors, compositions comprising them, and methods of their use
  申请人：Lexicon Pharmaceuticals, Inc.

  公开号：US08193202B2

  公开（公告）日：2012-06-05

  Inhibitors of LIM kinase 2 are disclosed, along with pharmaceutical compositions comprising them and methods of their use. Particular compounds are of the formula:

  本发明揭示了LIM激酶2的抑制剂，以及包含它们的制药组合物和它们的使用方法。特别的化合物的化学式如下：
• LIMK2 inhibitors, compositions comprising them and methods of their use
  申请人：Lexicon Pharmaceuticals, Inc.

  公开号：EP2674433A1

  公开（公告）日：2013-12-18

  Inhibitors of LIM kinase 2 are disclosed, along with pharmaceutical compositions comprising them and methods of their use. Particular compounds are of the formula (I).

  本文公开了 LIM 激酶 2 的抑制剂，以及包含这些抑制剂的药物组合物和使用方法。具体化合物如式 (I)。
• Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma
  作者：Bryce A. Harrison、Zheng Y. Almstead、Hugh Burgoon、Michael Gardyan、Nicole C. Goodwin、Jason Healy、Ying Liu、Ross Mabon、Brett Marinelli、Lakshman Samala、Yulian Zhang、Terry R. Stouch、N. Andrew Whitlock、Suma Gopinathan、Beth McKnight、Shuli Wang、Nita Patel、Alan G. E. Wilson、Brian D. Hamman、Dennis S. Rice、David B. Rawlins

  DOI：10.1021/ml500367g

  日期：2015.1.8

  The structure of LX7101, a dual LIM-kinase and ROCK inhibitor for the treatment of ocular hypertension and associated glaucoma, is disclosed. Previously reported LIM kinase inhibitors suffered from poor aqueous stability due to solvolysis of the central urea. Replacement of the urea with a hindered amide resulted in aqueous stable compounds, and addition of solubilizing groups resulted in a set of compounds with good properties for topical dosing in the eye and good efficacy in a mouse model of ocular hypertension. LX7101 was selected as a clinical candidate from this group based on superior efficacy in lowering intraocular pressure and a good safety profile. LX7101 completed IND enabling studies and was tested in a Phase 1 clinical trial in glaucoma patients, where it showed efficacy in lowering intraocular pressure.
• US8193202B2
  申请人：——

  公开号：US8193202B2

  公开（公告）日：2012-06-05